J. Nathan Davis
About
In The Last Decade
J. Nathan Davis
26 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 81
- Molecular Biology 975
- Oncology 375
- Hematology 373
- Cell Biology 166
- Public Health, Environmental and Occupational Health 152
Countries citing papers authored by J. Nathan Davis
This map shows the geographic impact of J. Nathan Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Nathan Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Nathan Davis more than expected).
Fields of papers citing papers by J. Nathan Davis
This network shows the impact of papers produced by J. Nathan Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Nathan Davis. The network helps show where J. Nathan Davis may publish in the future.
Co-authorship network of co-authors of J. Nathan Davis
This figure shows the co-authorship network connecting the top 25 collaborators of J. Nathan Davis. A scholar is included among the top collaborators of J. Nathan Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Nathan Davis. J. Nathan Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 7 | |
| 3 | 10 | |
| 4 | 24 | |
| 5 | 25 | |
| 6 | 21 | |
| 7 | 38 | |
| 8 | 45 | |
| 9 | 91 | |
| 10 | 121 | |
| 11 | Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. | 87 |
| 12 | 50 | |
| 13 | Comparison of potential markers of farnesyltransferase inhibition. | 103 |
| 14 | A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. | 201 |
| 15 | 33 | |
| 16 | 35 | |
| 17 | 49 | |
| 18 | 29 | |
| 19 | 6 | |
| 20 | 21 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.